Vyndaqel (Tafamidis Meglumine) Patent Expiration, LOE Window & CMS Spending

Vyndaqel (Tafamidis Meglumine) by Pfizer: FDA Orange Book core substance LOE 2026-12-19, 0 AB generics, $304.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN211996 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-12-19
Last Listed Patent or Exclusivity Date2026-12-19
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$304.5M
2024 Medicare Part D Spend$303.6M
2024 Medicaid Spend$927K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.